Rare Disease Advocate - BioTech Funding Portal

Content reflects the views of the posting party and is provided for informational purposes only. It does not constitute a solicitation, recommendation, endorsement, or investment advice by BioTech Funding Portal. All content is subject to the portal’s Community Content Guidelines.

Chris Hopkins

CEO

Glafabra Therapeutics

Developing durable cell-based gene therapies for Fabry, Gaucher, Pompe & other enzyme deficiencies. View (0) Answers

Ask a Question

Tetsu Yung

Director of JAPAC Strategy

Glafabra Therapeutics

Building JAPAC strategy for Glafabra to advance durable, cell-based therapy for Fabry disease patients View (0) Answers

Ask a Question

TJ Cradick

Principal / Fractional CSO

Gene Editing Frontiers LLC

>25 years at forefront of Gene Editing: Head of Genome Editing CRISPR Tx, Excision CSO, HuidaGene CTO & Consulting at Gene Editing Frontiers View (0) Answers

Ask a Question

Kelvyn Cullimore

President & CEO

BioUtah

Kelvyn Cullimore was named President & CEO of BioUtah, the trade association for life sciences companies in Utah, in October 2018. Mr. Cull View (0) Answers

Ask a Question

Taylor Kane

Patient Engagement Consultant

Patient engagement consulting specializing in rare disease, reproductive genetics, and IVF with PGT-M View (0) Answers

Ask a Question

Kevin Marhenke

View (0) Answers

Ask a Question

Want to see more? Login or Register for Free.

Disclosures

© 2026 BioTech Social Inc. (“BSI”). This website and related services are provided by BSI and BioTech Funding Portal LLC (“BFP”), a wholly owned subsidiary of BSI (collectively, “BioTech Social”). Certain regulated crowdfunding services and offerings available through this website are operated by BFP, while other content, features, and services may be provided, maintained, or supervised by BSI.

BFP is a FINRA member funding portal (FPRD #334156) registered with the U.S. Securities and Exchange Commission (“SEC”). Through BFP, eligible issuers may conduct offerings pursuant to Regulation Crowdfunding, and persons 18 years of age or older may review and invest in such offerings.

Offerings conducted by life science companies are subject to industry-specific risks, including but not limited to regulatory approval and clearance risk, clinical and development risk, intellectual property risk, commercialization risk, manufacturing and supply chain risk, and capital formation risk. Please review the applicable offering materials for additional information.

Investment offerings are speculative, illiquid, and involve a high degree of risk, including the possible loss of an investor's entire investment. Past performance of any security, company, project, management team, or technology is not indicative of future results.

Neither BFP nor BSI provides investment advice, recommendations, or suitability determinations. Neither BFP nor BSI provides tax, accounting, legal, or regulatory advice. Investors must make their own investment decisions and conduct their own due diligence prior to investing. The content contained herein does not constitute a solicitation of an offer to buy or sell any security.

By using this website, you agree to be bound by our Terms of Use, Privacy Policy, and Electronic Consent. Please review these carefully before using the website.

Hide Disclosure